120 Hours Simultaneous Infusion of Cisplatin and Fluorouracil in Metastatic Breast Cancer

Hidalgo, O. Fernández; Gonzalez, F.; Gil, AB Guisado; Campbell, W. I.; Barrajón, E.; Lacave, A.J.

doi:10.1097/00000421-198910000-00007

Cited by 27 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each chemotherapeutic agent (gemcitabine, 5-FU and cisplatin) has an antitumor effect. Cisplatin has a synergistic effect as a modulator of 5-FU [30][31][32] . Although the mechanism is not clear, addition of gemcitabine might have a more potent antineoplastic effect compared with intra-arterial low-dose cisplatin and 5-FU alone.…”

Section: Discussionmentioning

confidence: 99%

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases

Uka

Aikata²,

Takaki³

et al. 2008

WJG

View full text Add to dashboard Cite

The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC). Systemic gemcitabine chemotherapy seems effective in many cancers. We report the results of combination therapy with systemic gemcitabine, intra-arterial low-dose cisplatin and 5-FU (GEMFP). Seven patients with non-resectable advanced HCC were treated with GEMFP.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases

Uka

Aikata²,

Takaki³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…In eight studies testing the association of cisplatin and continuous infusion 5-FU, the response rate ranged between 11 and 48% as a second- or third-line approach [20,21,22,23,24,25,26,27], while in a first-line study, the response rate was 62% [20]. In these studies, continuous 5-FU was delivered for a few days.…”

Section: Introductionmentioning

confidence: 99%

Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes

Donadio

Ardine²,

Berruti³

et al. 2005

Oncology

View full text Add to dashboard Cite

Background: Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer is challenging. This study evaluated the activity and safety of a combination of cisplatin and capecitabine in this setting. Patients and Methods: Thirty-nine consecutive patients entered the study. All had experienced failures or relapse after previous treatment with anthracyclines and taxanes plus/minus other chemotherapeutic regimens. The present treatment consisted of intravenous cisplatin 20 mg/m² every week for 6 weeks, followed by 1 week of rest, and oral capecitabine 1,000 mg/m² twice daily for 14 days, followed by a 7-day rest period. Results: Objective response was obtained in 14 patients (35.9%), with complete remission in 3 (7.7%). Median time to progression was 5.2 months and survival was 10.9 months in the entire population and 8.7 and 16.5 months in the responding patients, respectively. The dose-limiting toxicity for the regimen was leucopenia, while gastrointestinal discomfort was the most frequent cause of capecitabine reduction or delay. Conclusions: The cisplatin and capecitabine combination regimen is active and manageable. It seems to be non-cross resistant to anthracyclines and taxanes.

show abstract

“…Subsequent groups of patients received escalated doses of CDDP and VP-16 until a maximally tolerated dose was determined. CDDP and VP-16 were given as a bolus over 2 hours in clinic on days 8,15,22,29,36,43,50,57, and every 2 weeks thereafter. Both agents were delivered in one liter of fluid sequentially, with VP-16 administered first.…”

Section: Methodsmentioning

confidence: 99%

Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study

Saphner

Tormey

Albertini

1991

Cancer

View full text Add to dashboard Cite

Continuous infusion 5‐fluorouracil (CI 5‐FU) and the combination of cisplatin (CDDP) plus etoposide (VP‐16) have emerged as salvage regimens for metastatic breast carcinoma (MBC). In this study, 18 patients (15 with MBC) were entered into a Phase I study to determine the maximum intermittent doses of CDDP and VP‐16 that could be added to 200 mg/m2/d CI 5‐FU. The maximum tolerated dose of the combination was 40 mg/m2 of CDDP and 60 mg/m2 of VP‐16 weekly for the first 8 weeks and every other week thereafter. The dose‐limiting toxicities of the regimen were myelosuppression and thrombocytopenia. Two complete responses (both patients had received no previous chemotherapy) and one partial response were noticed. This regimen at the doses described here is appropriate for Phase II trials as an alternative to doxorubicin‐based regimens for MBC. Cancer 68:2359–2362, 1991.

show abstract

120 Hours Simultaneous Infusion of Cisplatin and Fluorouracil in Metastatic Breast Cancer

Cited by 27 publications

References 0 publications

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases

Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes

Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study

Contact Info

Product

Resources

About